Bridgewater Advisors Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 36.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,549 shares of the company’s stock after purchasing an additional 6,075 shares during the quarter. Johnson & Johnson accounts for about 1.0% of Bridgewater Advisors Inc.’s investment portfolio, making the stock its 18th largest position. Bridgewater Advisors Inc.’s holdings in John & Johnson were worth $3,684,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC raised its position in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the stock company’ valued at $32,000 after buying an additional 78 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson in the second quarter worth $39,000. Cardinal Capital Management Inc. increased its position in Johnson & Johnson3 by the 33% second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. First Bank & Trust increased its position in Johnson & Johnson by 69.6% in an er second. & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LL C bought a new stake in Johnson & Johnson in the second quarter worth $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on JNJ shares. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective on the stock. Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven equities research Analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $182.42.
Insider Buying and Selling
In related news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion, The executive vice president now directly owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, LEV sold 76,923 shares of the stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice of sha5 president now owns directly 26 the company’s stock, valued at $22,354,891.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Peter Fasolo sold 22,864 share s of the stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the sale, the vice president now directly owns 114,676 shares of the company, valued at stock $18,864,202. The disclosure for this sale can be found here. Insiders sold a total of 300,750 shares of company stock valued at $52,311,677 over the last three months. 0.35% of the stock is owned by company insiders.
Johnson & Johnson Stock Down 0.3 %
Shares of JNJ opened at $173.43 on Monday. The firm has a market capitalization of $453.43 billion, a P/E ratio of 24.15, a P/E/G ratio of 3.28 and a beta of 0.56. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The firm has a fifty day moving average price of $176.32 and a 200-day moving average price of $171.47.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same period in the prior year, the firm earned $2.60 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.61% The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby INTER ISTER brands; oral care under the Lbrs skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or out comments about this story [email protected].
Before you consider Johnson & Johnson, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before market the broader on… and Johnson & Johnson wasn’t on the list.
While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
